1227605-52-8

Basic information

• Product Name: 2-broMo-5-chloronicotinaldehyde
• Synonyms: 2-broMo-5-chloronicotinaldehyde;2-bromo-5-chloropyridine-3-carbaldehyde
• CAS NO: 1227605-52-8
• Molecular Formula: C6H3BrClNO
• Molecular Weight: 220.45112
• Mol File: 1227605-52-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 278.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.800±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.29±0.20(Predicted)
• CAS DataBase Reference: 2-broMo-5-chloronicotinaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-broMo-5-chloronicotinaldehyde(1227605-52-8)
• EPA Substance Registry System: 2-broMo-5-chloronicotinaldehyde(1227605-52-8)

Safety Data

• Hazardous Substances Data: 1227605-52-8(Hazardous Substances Data)

Usage

General Description

2-Bromo-5-chloronicotinaldehyde is a chemical compound with the molecular formula C6H3BrClNO. It is a synthetic intermediate used in the pharmaceutical and agrochemical industries for the production of various compounds, including pesticides and pharmaceuticals. 2-broMo-5-chloronicotinaldehyde is known for its versatile reactivity and potential applications in organic synthesis. It is commonly used as a building block in the synthesis of complex molecules, and its unique chemical properties make it valuable for the development of new drugs and agricultural products. Additionally, it is important to handle this compound with care due to its potential hazards and toxic nature.

Upstream product

• 137628-17-2 2,3-dibromo-5-chloro-pyridine 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1646178-60-0 3-((5-chloro-3-(hydroxymethyl)pyridin-2-yl)methyl)-1-phenylindolin-2-one 
• 1646178-21-3 C₂₁H₁₆Cl₂N₂O 
• 1646178-28-0 (S)-3-chloro-1'-phenyl-5,7-dihydrospiro[cyclopenta[b]pyridin]-2'-one 

Relevant articles and documents

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

Calcitonin gene-related peptide (CGRP) receptor antagonist treatment of migraine

Migraine is ranked as the sixth cause of years lost due to disability, with around 1.04 billion migraine sufferers globally. Triptans are considered the standard for acute migraine treatment, but an important number of migraineurs do not respond to them and these drugs are contraindicated in patients with cardiovascular disease. Migraine therapy is currently undergoing tremendous development, i.e., 5-HT1F receptor agonists (ditans), anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies, and small-molecule CGRP receptor antagonists (gepants). Ubrogepant (MK-1620) is a small-molecule, potent and selective CGRP receptor antagonist. In two phase III clinical trials (ACHIEVE I and II), ubrogepant showed, at 2 hours, significant percentages of pain freedom, and absence of the most bothersome symptoms in migraine patients. In a phase III study to assess the long-term (52-week) safety and tolerability, ubrogepant displayed good tolerability, and no signs of hepatic toxicity. In March 2019, the U.S. Food and Drug Administration accepted the new drug application (NDA) for ubrogepant for the acute treatment of migraine.

Discovery and application of doubly quaternized cinchona-alkaloid-based phase-transfer catalysts

We report the discovery of novel N,N'-disubstituted cinchona alkaloids as efficient phase-transfer catalysts for the assembly of stereogenic quaternary centers. In comparison to traditional cinchona-alkaloid-based phase-transfer catalysts, these new catal